Ribozyme therapy for HIV infection

Advanced Drug Delivery Reviews

Volumn 44, Issue 1, 2000, Pages 71-78

  Rossi, John J ^a  

^a City of Hope   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INFUSION; DRUG PRODUCTS; DRUG THERAPY; ENZYME INHIBITION; GENETIC ENGINEERING; VIRUSES;

RIBOZYME THERAPY;

CONTROLLED DRUG DELIVERY;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RIBOZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CLINICAL TRIAL; CLONING VECTOR; ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; RNA CLEAVAGE; RNA STRUCTURE; VIRUS CULTURE; VIRUS INHIBITION;

EID: 0034739591     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(00)00085-5     Document Type: Article

References (52)

1. Kruger K., Grabowski P.J., Zaug A.J., Sands J., Gottschling D.E., Cech T.R. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell. 31:1982;147-157.
2. Guerrier-Takada C., Gardiner K., Marsh T., Pace N., Altman S. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell. 35:1983;849-857.
3. Rossi J.J. Practical ribozymes. Making ribozymes work in cells. Curr. Biol. 4:1994;469-471.
4. Rossi J.J., Sarver N. Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents. Adv. Exp. Med. Biol. 312:1992;95-109.
5. Castanotto D., Rossi J.J., Deshler J.O. Biological and functional aspects of catalytic RNAs. Crit. Rev. Eukaryotic Gene Expr. 2:1992;331-357.
6. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., Berger E.A. CC-CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1996;1955-1958.
7. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., Cayanan C., Maddon P.J., Koup R.A., Moore J.P., Paxton W.A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 [see comments]. Nature. 381:1996;667-673.
8. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1 [see comments]. Nature. 381:1996;661-666.
9. Haseloff J., Gerlach W.L. Simple RNA enzymes with new and highly specific endoribonuclease activities. 1988 [classical article]. Biotechnology. 24:1992;264-269.
10. Ruffner D.E., Stormo G.D., Uhlenbeck O.C. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry. 29:1990;10695-10702.
11. Hampel A. The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy. Prog. Nucleic Acid Res. Mol. Biol. 58:1998;1-39.
12. Sarver N., Cantin E.M., Chang P.S., Zaia J.A., Ladne P.A., Stephens D.A., Rossi J.J. Ribozymes as potential anti-HIV-1 therapeutic agents. Science. 247:1990;1222-1225.
13. Gervaix A., Li X., Kraus G., Wong-Staal F. Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J. Virol. 71:1997;3048-3053.
14. Kuwabara T., Amontov S.V., Warashina M., Ohkawa J., Taira K. Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes. Nucleic Acids Res. 24:1996;2302-2310.
15. Ramezani A., Ding S.F., Joshi S. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes. Gene Ther. 4:1997;861-867.
16. Chen C.J., Banerjea A.C., Harmison G.G., Haglund K., Schubert M. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. 20:1992;4581-4589.
17. Leavitt M.C., Yu M., Yamada O., Kraus G., Looney D., Poeschla E., Wong-Staal F. Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum. Gene Ther. 5:1994;1115-1120.
18. Li X., Gervaix A., Kang D., Law P., Spector S.A., Ho A.D., Wong-Staal F. Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies. Gene Ther. 5:1998;233-239.
19. Rosenzweig M., Marks D.F., Hempel D., Heusch M., Kraus G., Wong-Staal F., Johnson R.P. Intracellular immunization of rhesus CD34+ hematopoietic progenitor cells with a hairpin ribozyme protects T cells and macrophages from simian immunodeficiency virus infection. Blood. 90:1997;4822-4831.
20. Yu M., Leavitt M.C., Maruyama M., Yamada O., Young D., Ho A.D., Wong-Staal F. Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 92:1995;699-703.
21. Wang L., Witherington C., King A., Gerlach W.L., Carr A., Penny R., Cooper D., Symonds G., Sun L.Q. Preclinical characterization of an anti-tat ribozyme for therapeutic application. Hum. Gene Ther. 9:1998;1283-1291.
22. Wong-Staal F., Poeschla E.M., Looney D.J. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum. Gene Ther. 9:1998;2407-2425.
23. Bauer G., Valdez P., Kearns K., Bahner I., Wen S.F., Zaia J.A., Kohn D.B. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood. 89:1997;2259-2267.
24. Ho A.D., Li X., Lane T.A., Yu M., Law P., Wong-Staal F. Stem cells as vehicles for gene therapy: novel strategy for HIV infection. Stem Cells. 13:(Suppl. 3):1995;100-105.
25. Gervaix A., Schwarz L., Law P., Ho A.D., Looney D., Lane T., Wong-Staal F. Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-infected individuals [see comments]. Hum. Gene Ther. 8:1997;2229-2238.
26. Zhou C., Bahner I.C., Larson G.P., Zaia J.A., Rossi J.J., Kohn E.B. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene. 149:1994;33-39.
27. Morgan R.A., Anderson W.F. Human gene therapy. Annu. Rev. Biochem. 62:1993;191-217.
28. Uchida N., He D., Friera A.M., Reitsma M., Sasaki D., Chen B., Tsukamoto A. The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. Blood. 89:1997;465-472.
29. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector [see comments]. Science. 272:1996;263-267.
30. Dropulic B., Hermankova M., Pitha P.M. A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc. Natl. Acad. Sci. U.S.A. 93:1996;11103-11108.
31. Strayer D.S., Kondo R., Milano J., Duan L.X. Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells. Gene Ther. 4:1997;219-225.
32. Podsakoff G., Wong K.K. Jr., Chatterjee S. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J. Virol. 68:1994;5656-5666.
33. Chatterjee S., Li W., Wong C.A., Fisher-Adams G., Lu D., Guha M., Macer J.A., Forman S.J., Wong K.K. Jr. Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Blood. 93:1999;1882-1894.
34. Fisher-Adams G., Wong K.K. Jr., Podsakoff G., Forman S.J., Chatterjee S. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood. 88:1996;492-504.
35. Chatterjee S., Johnson P.R., Wong K.K. Jr. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science. 258:1992;1485-1488.
36. Westaway S.K., Cagnon L., Chang Z., Li S., Li H., Larson G.P., Zaia J.A., Rossi J.J. Virion encapsidation of tRNA(3Lys)-ribozyme chimeric RNAs inhibits HIV infection. Antisense Nucleic Acid Drug. Dev. 8:1998;185-197.
37. Westaway S.K., Larson G.P., Li S., Zaia J.A., Rossi J.J. A chimeric tRNA(Lys3)-ribozyme inhibits HIV replication following virion assembly. Nucleic Acids Symp. Ser. 33:1995;194-199.
38. Yamada O., Kraus G., Luznik L., Yu M., Wong-Staal F. A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J. Virol. 70:1996;1596-1601.
39. Michienzi A., Conti L., Varano B., Prislei S., Gessani S., Bozzoni I. Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line. Hum. Gene Ther. 9:1998;621-628.
40. Bertrand E., Castanotto D., Zhou C., Carbonnelle C., Lee N.S., Good P., Chatterjee S., Grange T., Pictet R., Kohn D., Engelke D., Rossi J.J. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA. 3:1997;75-88.
41. Zhou C., Bahner I., Rossi J.J., Kohn D.B. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition. Antisense Nucleic Acid Drug Dev. 6:1996;17-24.
42. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane. G protein-coupled receptor [see comments]. Science. 272:1996;872-877.
43. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., Wu L., Mackay C.R., LaRosa G., Newman W., Gerard N., Gerard C., Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1996;1135-1148.
44. Rana S., Besson G., Cook D.G., Rucker J., Smyth R.J., Yi Y., Turner J.D., Guo H.H., Du J.G., Peiper S.C., Lavi E., Samson M., Libert F., Liesnard C., Vassart G., Doms R.W., Parmentier M., Collman R.G. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation. J. Virol. 71:1997;3219-3227.
45. Biti R., Ffrench R., Young J., Bennetts B., Stewart G., Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele [letter; comment]. Nat. Med. 3:1997;252-253.
46. Stewart G.J., Ashton L.J., Biti R.A., Ffrench R.A., Bennetts B.H., Newcombe N.R., Benson E.M., Carr A., Cooper D.A., Kaldor J.M. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS. 11:1997;1833-1838.
47. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene [see comments]. Nature. 382:1996;722-725.
48. Mellors J.W., Rinaldo C.R. Jr., Gupta P., White R.M., Todd J.A., Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma [see comments] [published erratum appears in Science 1997 Jan 3;275(5296):14]. Science. 272:1996;1167-1170.
49. Carroll R.G., Riley J.L., Levine B.L., Feng Y., Kaushal S., Ritchey D.W., Bernstein W., Weislow O.S., Brown C.R., Berger E.A., June C.H., St. Louis D.C. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science. 276:1997;273-276.
50. Simmons G., Clapham P.R., Picard L., Offord R.E., Rosenkilde M.M., Schwartz T.W., Buser R., Wells T.N.C., Proudfoot A.E. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science. 276:1997;276-279.
51. Perelson A.S., Essunger P., Ho D.D. Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS. 11:1997;S17-24.
52. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., Markowitz M., Ho D.D. Decay characteristics of HIV-1-infected compartments during combination therapy [see comments]. Nature. 387:1997;188-191.